Pacira BioSciences partners with Molteni to expand EXPAREL distribution in EU and U.K.
Pacira BioSciences has entered into an exclusive agreement with Molteni Farmaceutici for the commercialization of its long-acting analgesic, EXPAREL, across the European Union and United Kingdom. The deal includes an upfront payment to Pacira, a supply price arrangement, and future royalty payments based on sales in these territories. This partnership is expected to significantly expand the market reach of EXPAREL, which has already gained traction as a popular pain management solution for surgical patients. Molteni's established presence in Europe positions it well to drive adoption among healthcare providers across multiple countries. The collaboration reflects Pacira’s strategy to leverage third-party commercialization partners in key international markets. The financial terms of the agreement were not disclosed, but such partnerships often signal confidence from both parties regarding product demand and market potential.
Tickers: $PCRX